Imagen de Portada

Potential drug interaction between calcitonin gene‐related peptide antagonists and neonatal Fc receptor inhibitors

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Alex Harlan, Kevin Weber
Formato:	Artículo Open Access
Publicado:	Wiley 2025
Materias:	Headache: The Journal of Head and Face Pain
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Development and pharmacological characterization of novel multi‐ calcitonin gene‐related peptide and pituitary adenylate cyclase‐activating peptide receptor antagonists
por: Zoe Tasma, et al.
Publicado: (2025)

Genetic migraine disorders and the response to calcitonin gene‐related peptide antagonist treatment
por: Andrea M. Kuczynski, et al.
Publicado: (2025)

Evaluating dual calcitonin gene‐related peptide antagonists for chronic migraine prevention
por: Kara S. Graves, et al.
Publicado: (2026)

Treatment of abdominal migraine in an 8‐year‐old child with calcitonin gene‐related peptide receptor antagonist: A case report
por: Yunzhu Tang, et al.
Publicado: (2025)

Arterial hypertension: A safety risk of calcitonin gene‐related peptide ligand and receptor blocker class
por: David Croteau, et al.
Publicado: (2026)

Migraine, idiopathic intracranial hypertension, and calcitonin gene‐related peptide antibodies
por: Irina Krikova, et al.
Publicado: (2024)

Amplifying and ameliorating light avoidance in mice with photoreceptor targeting and calcitonin gene‐related peptide sensitization
por: Eric A. Kaiser, et al.
Publicado: (2025)

Patient reported outcomes and the real‐world use of calcitonin gene–related peptide medications in migraine
por: Samuel K. Peasah, et al.
Publicado: (2024)

Persistence, effectiveness, and tolerability of anti‐calcitonin gene–related peptide monoclonal antibodies in patients with chronic migraine
por: Anna de Dios, et al.
Publicado: (2024)

Patient satisfaction with calcitonin gene‐related peptide monoclonal antibodies in migraine: A multicenter prospective cohort study
por: Alba López‐Bravo, et al.
Publicado: (2025)

Letter to the Editor regarding “Persistence, effectiveness, and tolerability of anti‐calcitonin gene‐related peptide monoclonal antibodies in patients with chronic migraine”
por: Joaquín Borrás‐Blasco, et al.
Publicado: (2025)

Differences in circulating alpha‐calcitonin gene–related peptide levels in inflammatory bowel disease and its relation to migraine comorbidity: A cross‐sectional study
por: Marta Pascual‐Mato, et al.
Publicado: (2024)

The pathogenic role of calcitonin gene‐related peptide and predictors of new‐onset migraine and long‐term outcomes after transcatheter atrial septal defect closure
por: Tzu‐Hsuan Su, et al.
Publicado: (2024)

Comment on “Plasma calcitonin gene‐related peptide and nerve growth factor as headache and pain biomarkers in recently deployed soldiers with and without a recent concussion”
por: Gabriel Gárate, et al.
Publicado: (2024)

Nonspecific oral medications versus anti–calcitonin gene‐related peptide monoclonal antibodies for migraine: A systematic review and meta‐analysis of randomized controlled trials
por: Jennifer Robblee, et al.
Publicado: (2024)

Author Response to Comment on “Plasma calcitonin gene‐related peptide and nerve growth factor as headache and pain biomarkers in recently deployed soldiers with and without a recent concussion”
por: Ann I. Scher, et al.
Publicado: (2024)

Calcitonin gene‐related peptide‐targeting therapies are a first‐line option for the prevention of migraine: An American Headache Society position statement update
por: Andrew C. Charles, et al.
Publicado: (2024)

Calcitonin gene‐related peptide and headache: Comparison of two commonly used assay kits highlights the perils of measuring neuropeptides with enzyme‐linked immunosorbent assays
por: Michael L. Garelja, et al.
Publicado: (2025)

Response to: Calcitonin gene‐related peptide and headache: Comparison of two commonly used assay kits highlights the perils of measuring neuropeptides with enzyme‐linked immunosorbent assays
por: Alicia Alpuente, et al.
Publicado: (2026)

Response to Letter to the Editor regarding “Calcitonin gene‐related peptide and headache: Comparison of two commonly used assay kits highlights the perils of measuring neuropeptides with enzyme‐linked immunosorbent assays”
por: Michael L. Garelja, et al.
Publicado: (2026)

Assessment of pharmacokinetic and pharmacodynamic interactions between zavegepant and sumatriptan: A phase 1, randomized, placebo‐controlled study in healthy adults
por: Rajinder Bhardwaj, et al.
Publicado: (2024)

Synergistic effect of combining dual enkephalinase inhibitor PL37 and sumatriptan in a preclinical model of migraine
por: Jeanne Rossignol, et al.
Publicado: (2024)

Do antithrombotic drugs have a role in migraine prevention? A systematic review
por: Federico De Santis, et al.
Publicado: (2025)

A study of migraine‐like headache caused by topical aryl hydrocarbon receptor agonist tapinarof
por: Toshiyuki Hikita, et al.
Publicado: (2026)

A randomized sequential cross‐over trial evaluating five purportedly ICP ‐lowering drugs in idiopathic intracranial hypertension
por: James L. Mitchell, et al.
Publicado: (2025)

Evaluating associations of migraine‐related vertigo
por: Nazia Karsan, et al.
Publicado: (2025)

Anxiety and depressive symptoms and migraine‐related outcomes in children and adolescents
por: Bilal Ahmed Rizvi, et al.
Publicado: (2024)

Identifying cognitive‐affective mechanisms underlying disability in episodic migraine: Using the fear avoidance model to examine interactions
por: Janosch Fox, et al.
Publicado: (2025)

Anxiety, depression, and headache‐related disability in a large pediatric clinic–based sample
por: Christina Murphy, et al.
Publicado: (2024)

Headache‐related disability as a function of migraine aura: A daily diary study
por: Delora E. Denney, et al.
Publicado: (2024)

Causal associations between genetically predicted placental weight and migraine
por: Chung‐Chih Liao, et al.
Publicado: (2025)

Time to reconsider the association between migraine and white matter hyperintensities?
por: Anders Hougaard
Publicado: (2025)

Investigating the causal and genetic relationship between migraine and Parkinson's disease
por: Ming‐Gang Deng, et al.
Publicado: (2024)

OnabotulinumtoxinA as a promising treatment for primary trochlear headache: A retrospective case series
por: Alex Jaimes, et al.
Publicado: (2024)

Effectiveness of switching strategies in CGRP monoclonal antibody therapy for migraine: A retrospective cohort study
por: Alex Jaimes, et al.
Publicado: (2024)

The association between posttraumatic stress disorder and migraine: A systematic review
por: Lucie Nitsche, et al.
Publicado: (2026)

Association between migraine and exclusive breastfeeding: A cross‐sectional study
por: Manav V. Vyas, et al.
Publicado: (2024)

The impact of fear of attacks on pain‐related disability in cluster headache: Insights from the fear avoidance model
por: Janosch Fox, et al.
Publicado: (2024)

Association between wildfire smoke exposure and pediatric emergency department visits for headache
por: Hannah F. J. Shapiro, et al.
Publicado: (2025)

No differences in subcortical volume between people with and without migraine: A REFORM study
por: Basit Ali Chaudhry, et al.
Publicado: (2025)